胶质瘤干细胞的分子靶向治疗

doi:10.3760/cma.j.issn.1673422X.2016.12.013

摘要/Abstract

摘要： 胶质瘤干细胞（GSC)被认为是恶性胶质瘤迁移、复发和放化疗抵抗的根源。结合分子靶向药物在其他肿瘤领域走向临床的背景，针对GSC的分子靶向药物有望取得成功。目前，相关研究主要集中在Hedgehog、PI3K等通路，代表药物主要有环巴胺及其衍生物、雷帕霉素及其衍生物，经典药物三氧化二砷、二甲双胍也有抗GSC作用。

关键词: 神经胶质瘤, 干细胞, 分子靶向治疗

Abstract: Glioma stem cells (GSCs) are considered to be the root of migration, recurrence, and resistance to chemoradiotherapy in malignant glioma. With molecular targeting drugs becoming widespread in treating other cancers, the ones targeting GSCs could also be successful in the future. At present, relevant studies mainly concentrate in the hedgehog and PI3K pathways, and main representative drugs are cyclopamine and its derivatives, rapamycin and its derivatives, and some classical drugs like arsenic trioxide and metformin also performing the outcome of antiGSCs.

Key words: Glioma, Stem cells, Molecular targeted therapy

童鹿青, 汤天娇, 杨学军. 胶质瘤干细胞的分子靶向治疗[J]. 国际肿瘤学杂志, 2016, 43(12): 930-934.

TONG Lu-Qing, TANG Tian-Jiao, YANG Xue-Jun. Molecular targeted therapy for glioma stem cells[J]. Journal of International Oncology, 2016, 43(12): 930-934.

参考文献

［1］ Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cellsfrom concept to clinical application［J］. Cancer Lett, 2013, 338(1, SI): 3240. DOI: 10.1016/j.canlet.2012.05.033. ［2］ Balbous A, Renoux B, Cortes U, et al. Selective release of a cyclopamine glucuronide prodrug toward stemlike cancer cell inhibition in glioblastoma［J］. Mol Cancer Ther, 2014, 13(9): 21592169. DOI: 10.1158/15357163.MCT131038. ［3］ Fu J, Rodova M, Nanta R, et al. NPVLDE225 (erismodegib) inhibits epithelial mesenchymal transition and selfrenewal of glioblastoma initiating cells by regulating miR21, miR128, and miR200［J］. Neuro Oncol, 2013, 15(6): 691706. DOI: 10.1093/neuonc/not011. ［4］ Filbin MG, Dabral SK, PazyraMurphy MF, et al. Coordinate activation of Shh and PI3K signaling in PTENdeficient glioblastoma: new therapeutic opportunities［J］. Nat Med, 2013, 19(11): 1518. DOI: 10.1038/nm.3328. ［5］ Rodon J, Tawbi HA, Thomas AL, et al. A phase Ⅰ, multicenter, openlabel, firstinhuman, doseescalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors［J］. Clin Cancer Res, 2014, 20(7): 19001909. DOI: 10.1158/10780432.CCR131710. ［6］ Dixit D, Ghildiyal R, Anto NP, et al. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT1 induced apoptosis in a Ras/NFκB dependent manner［J］. Cancer Lett, 2013, 336(2): 347358. DOI: 10.1016/j.canlet.2013.03.025. ［7］ Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway［J］. J Clin Invest, 2011, 121(1): 148160. DOI: 10.1172/JCI42874. ［8］ Zhou WC, Cheng L, Shi Y, et al. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth［J］. Oncotarget, 2015, 6(35): 3730037315. DOI: 10.18632/oncotarget.5836. ［9］ Wen PY, Omuro A, Ahluwalia MS, et al. Phase Ⅰ doseescalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with highgrade glioma［J］. Neuro Oncol, 2015, 17(9): 12751283. DOI: 10.1093/neuonc/nov083. ［10］ BagciOnder T, Wakimoto H, Anderegg MA, et al. A dual PI3K/mTOR inhibitor, PI103, cooperates with stem celldelivered TRAIL in experimental glioma models［J］. Cancer Res, 2011, 71(1): 154163. DOI: 10.1158/00085472.CAN101601. ［11］ Sato A, Sunayama J, Okada M, et al. GliomaInitiating cell elimination by metformin activation of FOXO3 via AMPK［J］. Stem Cells Transl Med, 2012, 1(11): 811824. DOI: 10.5966/sctm.20120058. ［12］ Yu Z, Zhao G, Li P, et al. Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stemlike cells［J］. Oncol Lett, 2016, 11(4): 27922800. DOI: 10.3892/ol.2016.4315. ［13］ Zhuang WZ, Li BZ, Long LM, et al. Induction of autophagy promotes differentiation of gliomainitiating cells and their radiosensitivity［J］. Int J Cancer, 2011, 129(11): 27202731. DOI: 10.1002/ijc.25975. ［14］ GarrosRegulez L, Aldaz P, Arrizabalaga O, et al. mTOR inhibition decreases SOX2SOX9 mediated glioma stem cell activity and temozolomide resistance［J］. Expert Opin Ther Targets, 2016, 20(4): 393405. DOI: 10.1517/14728222.2016.1151002. ［15］ Ma DJ, Galanis E, Anderson SK, et al. A phase Ⅱ trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K［J］. Neuro Oncol, 2015, 17(9): 12611269. DOI: 10.1093/neuonc/nou328. ［16］ Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5year final analysis［J］. Ann Neurol, 2015, 78(6): 929938. DOI: 10.1002/ana.24523. ［17］ Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST1): a multicentre, randomised, placebocontrolled phase 3 trial［J］. Lancet, 2013, 381(9861): 125132. DOI: 10.1016/S01406736(12)611349. ［18］ Wen PY, Chang SM, Lamborn KR, et al. Phase Ⅰ/Ⅱ study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 0402［J］. Neuro Oncol, 2014, 16(4): 567578. DOI: 10.1093/neuonc/not247. ［19］ Kahn J, Hayman TJ, Jamal M, et al. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stemlike cells［J］. Neuro Oncol, 2014, 16(1): 2937. DOI: 10.1093/neuonc/not139. ［20］ Hu YY, Zheng MH, Cheng G, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patientderived glioma stem cells［J］. BMC Cancer, 2011, 11: 82. DOI: 10.1186/147124071182. ［21］ Yahyanejad S, King H, Iglesias VS, et al. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma［J］. Oncotarget, 2016, In press. DOI: 10.18632/oncotarget.9275. ［22］ Xu R, Shimizu F, Hovinga K, et al. Molecular and clinical effects of notch inhibition in glioma patients: a phase 0/Ⅰ trial［J］. Clin Cancer Res, 2016, In press. DOI: 10.1158/10780432.CCR160048. ［23］ Krop I, Demuth T, Guthrie T, et al. Phase Ⅰ pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK0752 in adult patients with advanced solid tumors［J］. J Clin Oncol, 2012, 30(19): 23072313. DOI: 10.1200/JCO.2011.39.1540. ［24］ Wickstrm M, Dyberg C, Milosevic J, et al. Wnt/betacatenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance［J］. Nat Commun, 2015, 6: 8904. DOI: 10.1038/ncomms9904. ［25］ KierulfVieira KS, Sandberg CJ, Grieg Z, et al. Wnt inhibition is dysregulated in gliomas and its reestablishment inhibits proliferation and tumor sphere formation［J］. Exp Cell Res, 2016, 340(1): 5361. DOI: 10.1016/j.yexcr.2015.12.010.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[3]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[4]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[5]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[6]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[7]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[8]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[9]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.
[12]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[13]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[14]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[15]	刘绍平, 罗汉传, 林书瀚, 罗家辉. 中晚期肝细胞癌介入及系统治疗的现状与研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 758-762.